Lenvatinib plus pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis
2019 ◽
Vol 153
(2)
◽
pp. 381-384
◽
2008 ◽
Vol 112
(1)
◽
pp. 56-63
◽
2017 ◽
Vol 4
(1)
◽
2007 ◽
Vol 29
(2)
◽
pp. 131-139
◽